United Therapeutics (NASDAQ:UTHR) CEO Sells $4,789,140.00 in Stock

Posted by Francis Steltz on Sep 15th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $504.12, for a total transaction of $4,789,140.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $163,558,205.16. The trade was a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded down $2.35 during trading on Tuesday, reaching $500.35. 1,326,936 shares of the company’s stock traded hands, compared to its average volume of 496,432. The stock has a market capitalization of $21.46 billion, a P/E ratio of 17.90, a price-to-earnings-growth ratio of 2.49 and a beta of 0.56. United Therapeutics Corporation has a 12 month low of $397.00 and a 12 month high of $609.35. The company has a 50 day moving average of $520.02 and a 200-day moving average of $540.96.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter last year, the company posted $6.41 earnings per share. United Therapeutics’s revenue was down 1.9% on a year-over-year basis. Equities research analysts predict that United Therapeutics Corporation will post 26.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Morgan Stanley set a $515.00 target price on United Therapeutics in a research report on Thursday, August 6th. Weiss Ratings cut United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Bank of America reduced their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Finally, Royal Bank Of Canada lowered their price target on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $646.00.

Read Our Latest Analysis on United Therapeutics

Institutional Trading of United Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in shares of United Therapeutics during the second quarter valued at $2,868,735,000. Janus Henderson Group PLC increased its stake in United Therapeutics by 8.9% during the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after buying an additional 70,829 shares during the period. Jupiter Topco LLC bought a new stake in shares of United Therapeutics during the 2nd quarter worth about $450,140,000. Norges Bank bought a new stake in shares of United Therapeutics during the 4th quarter worth about $293,418,000. Finally, Swedbank AB lifted its stake in shares of United Therapeutics by 0.7% in the 1st quarter. Swedbank AB now owns 327,122 shares of the biotechnology company’s stock worth $193,977,000 after acquiring an additional 2,350 shares during the period. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.